Audited Financial Results for the quarter and year ended March 31, 2026
ABBOTINDIA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.7 pts less than Nifty Midcap 150 and 0.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Abbott India reported full-year revenue of Rs 6,929 Cr, up 8.1% YoY from Rs 6,409 Cr. Profit after tax grew 9.7% to Rs 1,552 Cr from Rs 1,414 Cr. EPS stood at Rs 730.36 vs Rs 665.62 prior year. The company recognized Rs 18.10 Cr as incremental employee cost due to new labour codes. Other financial assets surged significantly to Rs 2,348 Cr (from Rs 756 Cr), largely reflecting fixed deposit investments. Cash flow from operations was strong at Rs 1,319 Cr, up from Rs 1,012 Cr. The Board recommended a final dividend of Rs 525/share plus a special dividend of Rs 131/share. Statutory auditors Walker Chandiok & Co. LLP issued an unmodified (clean) opinion with no qualifications or emphasis of matter.
Solid all-round performance with ~10% bottom-line growth. Clean audit with no red flags supports confidence in the stock. The sharp rise in financial assets reflects large cash accumulation, and the special dividend signals management's confidence in business continuity.